FREQUENCY OF ER, PR, AND HER2 POSITIVE CARCINOMA IN OPD SETTING AT JINNAH POSTGRADUATE MEDICAL CENTRE (JPMC), KARACHI

Abstract

Objective:
To determine the frequency of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu positivity and molecular subtypes of breast carcinoma among patients presenting to the outpatient department of a tertiary care public hospital.

Study Design:

Descriptive cross-sectional study.

Place and Duration of Study:

General Surgery Unit, Jinnah Postgraduate Medical Centre (JPMC), Karachi, from July 2024 to December 2024.

Methods:
A sample population of 57 women with a history of breast carcinoma, which was histologically confirmed, was gathered using non-probability consecutive sampling method. Immunohistochemical testing was done to establish the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu. Operation of HER2 overexpression was based on the intensity of 3+ on immunohistochemistry. Based on this, molecular subtypes were given. The statistical tests were conducted with SPSS 25, and frequencies and percentages of receptor status and molecular subtypes were calculated.

Results:
The mean age of patients was 48.6 ± 11.2 years. ER positivity was observed in 43 (75.4%) patients, PR positivity in 40 (70.2%), and HER2 positivity in 18 (31.6%). Luminal A was the most common molecular subtype, found in 27 (47.4%) cases, followed by Luminal B in 11 (19.3%), HER2-enriched in 7 (12.3%), and triple-negative breast cancer in 12 (21.0%) patients.

Conclusion:
The most common phenotype among patients who came to the outpatient department included hormone receptor positive breast cancer most commonly Luminal A subtype. Systematic receptor profiling is unavoidable in the development of proper therapeutic plans, especially when dealing with resource limited settings of the public sector.